A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer

被引：0
|
作者：
Hurwitz, H [1 ]
Fernando, N [1 ]
Yu, DH [1 ]
Morse, M [1 ]
Blobe, G [1 ]
Gockerman, J [1 ]
Odogwu, L [1 ]
Mahon, M [1 ]
Truax, R [1 ]
Franklin, A [1 ]
机构：
[1] Duke Univ, Durham, NC USA
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：285 / 285
页数：1
相关论文
共 50 条
  • [31] A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer.
    Overman, Michael J.
    Eng, Cathy
    Kee, Bryan K.
    Fogelman, David R.
    Fark, Christine
    Hippert, Rick
    Holter, Scott
    Issa, Jean-Pierre
    Hamilton, Stanley R.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [32] A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study
    Efrat Dotan
    Neal J. Meropol
    Barbara Burtness
    Crystal S. Denlinger
    James Lee
    David Mintzer
    Fang Zhu
    Karen Ruth
    Holly Tuttle
    Judi Sylvester
    Steven J. Cohen
    Journal of Gastrointestinal Cancer, 2012, 43 (4) : 562 - 569
  • [33] Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
    T Hoehler
    G von Wichert
    C Schimanski
    S Kanzler
    M H Moehler
    A Hinke
    T Seufferlein
    J Siebler
    A Hochhaus
    D Arnold
    M Hallek
    R Hofheinz
    U T Hacker
    British Journal of Cancer, 2013, 109 : 1408 - 1413
  • [34] Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
    Hoehler, T.
    von Wichert, G.
    Schimanski, C.
    Kanzler, S.
    Moehler, M. H.
    Hinke, A.
    Seufferlein, T.
    Siebler, J.
    Hochhaus, A.
    Arnold, D.
    Hallek, M.
    Hofheinz, R.
    Hacker, U. T.
    BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1408 - 1413
  • [35] A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results
    Kunz, P. L.
    Kuo, T.
    Kaiser, H. L.
    Norton, J. A.
    Longacre, T. A.
    Ford, J. M.
    Fisher, G. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
    Zeuli, M
    Nardoni, C
    Pino, MS
    Gamucci, T
    Gabriele, A
    Ferraresi, V
    Giannarelli, D
    Cognetti, F
    ANNALS OF ONCOLOGY, 2003, 14 (09) : 1378 - 1382
  • [37] Gene expression markers of resistance to capecitabine-oxaliplatin-bevacizumab treatment in metastatic colorectal cancer (mCRC).
    Rodriguez, Nuria
    Cejas, Paloma
    Moreno, Juan
    Mendiola, Marta
    Salud, Antonieta
    Jose Safont, Maria
    Garcia-Giron, Carlos
    Aparicio, Jorge
    Vera, Ruth
    Jorge Fernandez, Monica
    Escudero, Pilar
    Maurel, Juan
    Feliu, Jaime
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
    Pilar Garcia-Alfonso
    Manuel Chaves
    Andrés Muñoz
    Antonieta Salud
    Maria García-Gonzalez
    Cristina Grávalos
    Bartomeu Massuti
    Encarna González-Flores
    Bernardo Queralt
    Amelia López-Ladrón
    Ferran Losa
    Maria Jose Gómez
    Amparo Oltra
    Enrique Aranda
    BMC Cancer, 15
  • [39] CAPECITABINE AND OXALIPLATIN (XELOX) COMBINATION CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER-A PHASE II STUDY
    Tawfik, Hesham
    El-Deen, Hanan Gamal
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 98
  • [40] Phase I/II study of capecitabine(C)/oxaliplatin(O)/ irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Ou, K.
    Liu, X.
    Ma, X.
    Gao, L.
    Wang, Q.
    Yang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1514 - S1514
12345